348 related articles for article (PubMed ID: 28668223)
21. Small Molecule NF-κB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants.
Moser BA; Escalante-Buendia Y; Steinhardt RC; Rosenberger MG; Cassaidy BJ; Naorem N; Chon AC; Nguyen MH; Tran NT; Esser-Kahn AP
Front Immunol; 2020; 11():511513. PubMed ID: 33072085
[TBL] [Abstract][Full Text] [Related]
22. Cationic liposomes as vaccine adjuvants.
Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
[TBL] [Abstract][Full Text] [Related]
23. The path forward.
De Gregorio E
Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
[TBL] [Abstract][Full Text] [Related]
24. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
25. Adjuvants for veterinary vaccines--types and modes of action.
Gerdts V
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712
[TBL] [Abstract][Full Text] [Related]
26. Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants.
Fuentes R; Aguinagalde L; Pifferi C; Plata A; Sacristán N; Castellana D; Anguita J; Fernández-Tejada A
Front Immunol; 2022; 13():865507. PubMed ID: 35603193
[TBL] [Abstract][Full Text] [Related]
27. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
Leroux-Roels G
Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
[TBL] [Abstract][Full Text] [Related]
28. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
29. Adjuvants for porcine reproductive and respiratory syndrome virus vaccines.
Charerntantanakul W
Vet Immunol Immunopathol; 2009 May; 129(1-2):1-13. PubMed ID: 19157569
[TBL] [Abstract][Full Text] [Related]
30. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
31. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
32. Development of a minimal saponin vaccine adjuvant based on QS-21.
Fernández-Tejada A; Chea EK; George C; Pillarsetty N; Gardner JR; Livingston PO; Ragupathi G; Lewis JS; Tan DS; Gin DY
Nat Chem; 2014 Jul; 6(7):635-43. PubMed ID: 24950335
[TBL] [Abstract][Full Text] [Related]
33. Vaccine adjuvants: current status, research and development, licensing, and future opportunities.
Cui Y; Ho M; Hu Y; Shi Y
J Mater Chem B; 2024 May; 12(17):4118-4137. PubMed ID: 38591323
[TBL] [Abstract][Full Text] [Related]
34. Use of CpG oligodeoxynucleotides as immune adjuvants.
Klinman DM; Currie D; Gursel I; Verthelyi D
Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
[TBL] [Abstract][Full Text] [Related]
35. Vaccine adjuvants: Why and how.
Christensen D
Hum Vaccin Immunother; 2016 Oct; 12(10):2709-2711. PubMed ID: 27551808
[TBL] [Abstract][Full Text] [Related]
36. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
37. Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
Jennings R; Simms JR; Heath AW
Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256
[TBL] [Abstract][Full Text] [Related]
38. Current adjuvants and new perspectives in vaccine formulation.
Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
[TBL] [Abstract][Full Text] [Related]
39. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
40. Tailoring inorganic nanoadjuvants towards next-generation vaccines.
Li X; Wang X; Ito A
Chem Soc Rev; 2018 Jul; 47(13):4954-4980. PubMed ID: 29911725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
